EUVIMEDEUVIMED entdecken
BeobachtungsstudieKohortenstudieOpen Access · CC BY 4.0

Sentinel lymph node biopsy before and after neoadjuvant chemotherapy in cN0 breast cancer patients: impact on axillary morbidity and survival—a propensity score cohort study

Sergi Fernandez-Gonzalez, Catalina Falo, Maria J Pla, Miriam Campos, Carlos Ortega-Exposito, Raul Ortega, Maria Vicente, Ana Petit, Jan Bosch-Schips, Maria Teresa Bajen, Gabriel Reyes, Evelyn Martínez und 6 weitere

Breast Cancer Research and Treatment · 2024

DOI: 10.1007/s10549-024-07274-1 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Breast Cancer Research and Treatment, 2024. Verfasst von Sergi Fernandez-Gonzalez und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecology, Multidisciplinary Breast Cancer Unit, Hospital Universitari Bellvitge, Idibell, c/ Feixa Llarga s/n. Hospitalet de Llobrega…. Hauptthemen laut MEDLINE: Sentinel Lymph Node Biopsy, Breast Neoplasms, Neoadjuvant Therapy, Axilla. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universitat de Barcelona.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

In patients with clinically lymph node-negative (cN0) breast cancer, performing sentinel lymph node biopsy (SLNB) after neoadjuvant chemotherapy (NACT) has been preferentially embraced in comparison to before NACT. However, survival outcomes associated with both strategies remain understudied. We aimed to compare the axillary lymphadenectomy (ALND) rate, disease-free survival (DFS), and overall survival (OS), between two strategies.

Methods

We included 310 patients in a retrospective observational study. SNLB was performed before NACT from December 2006 to April 2014 (107 cases) and after NACT from May 2014 to May 2020 (203 patients). An inverse probability of treatment weighting (IPTW) method was applied to homogenize both groups. Hazard ratios (HR) and odd ratios (OR) are reported with 95% confidence intervals (95%CI).

Results

The lymphadenectomy rate was 29.9% before NACT and 7.4% after NACT ( p < 0.001), with an OR of 5.35 95%CI (2.7–10.4); p = .002. After 4 years of follow-up, SLNB after NACT was associated with lower risk for DFS, HR 0.42 95%CI (0.17–1.06); p = 0.066 and better OS, HR 0.21 CI 95% (0.07–0.67); p = 0.009 than SLNB before NACT. After multivariate analysis, independent adverse prognostic factors for OS included SLNB before NACT, HR 3.095 95%CI (2.323–4.123), clinical nonresponse to NACT, HR 1.702 95% CI (1.012–2.861), and small tumors (cT1) with high proliferation index, HR 1.889 95% (1.195–2.985).

Conclusion

Performing SLNB before NACT results in more ALND and has no benefit for patient survival. These findings support discontinuing the practice of SLNB before NACT in patients with cN0 breast cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sentinel Lymph Node BiopsyBreast NeoplasmsNeoadjuvant TherapyAxillaPropensity ScoreLymph Node ExcisionHumansFemaleMiddle AgedRetrospective StudiesAdultAgedLymph NodesNeoplasm StagingLymphatic MetastasisDisease-Free SurvivalAntineoplastic Combined Chemotherapy ProtocolsPrognosisChemotherapy, AdjuvantMorbidity

Stichwörter der Autor:innen

Axillary lymph node dissectionBreast cancerNeoadjuvant chemotherapySentinel lymph node biopsy

Autor:innen und Institutionen

  • Department of Gynecology, Multidisciplinary Breast Cancer Unit, Hospital Universitari Bellvitge, Idibell, c/ Feixa Llarga s/n. Hospitalet de Llobregat, CP: 08907, Barcelona, Spain. sfernandezg@bellvitgehospital.cat.
  • Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona (UB), Feixa Llarga, s/n, 08907, l'Hospitalet de Llobregat, Spain. sfernandezg@bellvitgehospital.cat.
  • Department of Medical Oncology, Multidisciplinary Breast Cancer Unit, Institut Català d'Oncologia, Idibell, Barcelona, Spain.
  • Department of Gynecology, Multidisciplinary Breast Cancer Unit, Hospital Universitari Bellvitge, Idibell, c/ Feixa Llarga s/n. Hospitalet de Llobregat, CP: 08907, Barcelona, Spain.
  • Department of Radiology, Multidisciplinary, Breast Cancer Unit. Hospital Universitari Bellvitge, Idibell, Barcelona, Spain.
  • Department of Pathology, Multidisciplinary Breast Cancer Unit, Hospital Universitari Bellvitge, Idibell, Barcelona, Spain.

Förderung

  • Universitat de Barcelona

Zitieren

APA

Fernandez-Gonzalez, S., Falo, C., Pla, M. J., Campos, M., Ortega-Exposito, C., Ortega, R., Vicente, M., Petit, A., Bosch-Schips, J., Bajen, M. T., Reyes, G., Martínez, E., González-Viguera, J., Peñafiel, J., Stradella, A., Pernas, S., Ponce, J., & Garcia-Tejedor, A. (2024). Sentinel lymph node biopsy before and after neoadjuvant chemotherapy in cN0 breast cancer patients: impact on axillary morbidity and survival—a propensity score cohort study. Breast Cancer Research and Treatment. https://doi.org/10.1007/s10549-024-07274-1

Vancouver

Fernandez-Gonzalez S, Falo C, Pla MJ, Campos M, Ortega-Exposito C, Ortega R, et al. Sentinel lymph node biopsy before and after neoadjuvant chemotherapy in cN0 breast cancer patients: impact on axillary morbidity and survival—a propensity score cohort study. Breast Cancer Research and Treatment. 2024. doi:10.1007/s10549-024-07274-1

BibTeX
@article{FernandezGonzalez2024,
  author = {Fernandez-Gonzalez, Sergi and Falo, Catalina and Pla, Maria J and Campos, Miriam and Ortega-Exposito, Carlos and Ortega, Raul and Vicente, Maria and Petit, Ana and Bosch-Schips, Jan and Bajen, Maria Teresa and Reyes, Gabriel and Martínez, Evelyn and González-Viguera, Javier and Peñafiel, Judith and Stradella, Agostina and Pernas, Sonia and Ponce, Jordi and Garcia-Tejedor, Amparo},
  title = {Sentinel lymph node biopsy before and after neoadjuvant chemotherapy in cN0 breast cancer patients: impact on axillary morbidity and survival—a propensity score cohort study},
  journal = {Breast Cancer Research and Treatment},
  year = {2024},
  doi = {10.1007/s10549-024-07274-1}
}
Kostenlos starten →